\
&
Contact us
\
&
Contact us
Research and Innovation to strengthen Europe's industrial capacities and business perspectives, including Small and Medium Sized Enterprises (SMEs).
The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020 will support the development of technologies underpinning innovation across a range of sectors. Horizon 2020 will have a strong focus on developing European industrial capabilities in Key Enabling Technologies (KETs).
This part of the programme covers different areas :
Activities of the work programme will address the whole innovation chain with technology readiness levels spanning the crucial range from medium levels to high levels preceding mass production, and helping to bridge the gaps ("valley of death") in this range. These activities will be based on research and innovation agendas defined by industry and business, together with the research community, and have a strong focus on leveraging private sector investment.
For the higher technology readiness levels, dedicated support will therefore be provided for larger-scale pilot lines and demonstrator projects to facilitate industrial take-up and commercialisation. There will be a strong focus on the contribution of Key Enabling Technologies to societal challenges.
Interested in our testimonies?
Click here
mark.antonissen@vlaio.be
+32 2 432 43 05
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
